Drug profile · INN
deutivacaftor
ALYFTREK
deutivacaftor (ALYFTREK) is a cystic fibrosis transmembrane conductance regulator activator. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — deutivacaftor
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
deutivacaftor (ALYFTREK) is a cystic fibrosis transmembrane conductance regulator activator. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cystic fibrosis transmembrane conductance regulator activator
Primary target: Cystic fibrosis transmembrane conductance regulator
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12421251
Cystic fibrosis transmembrane conductance regulator modulating agents
granted -
US 12384790
Pteridinone compounds and uses thereof
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12324802
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 12281057
Carboxamides as modulators of sodium channels
granted -
US 12269831
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 12258333
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
granted -
US 12247021
Substituted tetrahydrofurans as modulators of sodium channels
granted -
US 12194138
Devices and methods for delivering therapeutics
granted -
US 12186306
Methods of treatment for cystic fibrosis
granted -
US 12168009
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 12031150
Methods, compositions and kits for increasing genome editing efficiency
granted -
US 11951212
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
granted -
US 11951206
Cell housing device
granted -
US 11919887
Substituted tetrahydrofurans as modulators of sodium channels
granted -
US 11873300
Crystalline forms of CFTR modulators
granted -
US 11866450
Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
granted -
US 11827627
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
granted -
US 11773119
Prodrugs of pyridone amides useful as modulators of sodium channels
granted -
US 11673864
Pyridone amides as modulators of sodium channels
granted
Frequently asked questions
What is deutivacaftor?
deutivacaftor (ALYFTREK) is a cystic fibrosis transmembrane conductance regulator activator. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for deutivacaftor?
ALYFTREK is a marketed brand name for deutivacaftor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of deutivacaftor?
deutivacaftor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.